readthroughSign in
CompanyMBRXNasdaqHouston, TX

Moleculin Biotech, Inc.

Moleculin Biotech develops Annamycin, an anthracycline in Phase 2/3 development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 17Latest story

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026